Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 8/20 | 0.81 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | PTPRB | P23467 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22089505 | 0.91 | STS (0.90) | STSJAK2JAK1GPR119KDM4E | |
| SCHEMBL28418216 | 0.91 | STS (0.90) | STSJAK2JAK1GPR119KDM4E | |
| SCHEMBL1970651 | 0.90 | STS (1.00) | STSGPR119KDM4EPKMPTPRB | |
| SCHEMBL3595487 | 0.84 | STS (0.65) | STSCA12CA1CA7CA14 | |
| SCHEMBL3588904 | 0.82 | STS (0.58) | STSCA1P2RY12 | |
| SCHEMBL38658608 | 0.82 | STS (0.62) | STSNAMPTNR1H2JAK2JAK1 | |
| SCHEMBL4921942 | 0.81 | TACR1 (0.56) | STSNAMPTTACR1 | |
| SCHEMBL22089512 | 0.79 | STS (0.80) | STSP2RY12GPR119PTPRBPTPN11 | |
| SCHEMBL28422820 | 0.79 | STS (0.80) | STSP2RY12GPR119 | |
| SCHEMBL21641290 | 0.79 | STS (0.52) | STSNAMPTTACR1JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111303146-A | 3-cyanopyridine compound, pharmaceutical composition containing same, preparation method and application thereof | 中国科学院上海药物研究所 | 2020-06-19 | — | — | CN | disclosed |
| WO-2020119590-A1 | 3-CYANOPYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USES THEREOF. | 中国科学院上海药物研究所 | 2020-06-18 | — | — | WO | disclosed |
| WO-2020119590-A1 | 3-CYANOPYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USES THEREOF. | 中国科学院上海药物研究所 | 2020-06-18 | — | — | WO | disclosed |
| US-20100137277-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| US-20100069350-A1 | New Pyridine Analogues III | ASTRAZENECA AB (SE) | 2010-03-18 | — | — | US | disclosed |
| EP-2111400-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS. | AstraZeneca AB (SE) | 2009-10-28 | — | — | EP | disclosed |
| US-20080312208-A1 | Pyridine Analogues | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080200448-A1 | reversible and selective purinergic receptor P2Y12 antagonists; anticoagulants; cardiovascular disorders; e.g. ethyl 2-acetoxy-6-{4-[(benzylsulfonyl)carbamoyl]piperidin-1-yl}-5-cyanonicotinate | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | disclosed |
| US-20080171732-A1 | New Pyridine Analogues IX 519 | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| WO-2008085117-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS. | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008085119-A1 | NEW PYRIDINE ANALOGUES VIII 518 | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
| EP-1904474-A1 | NEW PYRIDINE ANALOGUES | AstraZeneca AB (SE) | 2008-04-02 | — | — | EP | disclosed |
| US-20080039437-A1 | New Pyridine Analogues III | ASTRAZENECA AB (SE) | 2008-02-14 | — | — | US | disclosed |
| WO-2007008140-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171732-A1 | New Pyridine Analogues IX 519 | P2RY12, P2RY11, P2RY1 | STS 2088/4885CA12 3752/4885CA1 4482/4885 |
| US-20080039437-A1 | New Pyridine Analogues III | P2RY12, P2RY1, P2RY11 | STS 2526/4885CA12 4529/4885CA1 4845/4885 |
| US-20100069350-A1 | New Pyridine Analogues III | P2RY12, P2RY11, P2RY1 | STS 2643/4885CA12 3879/4885CA1 4624/4885 |
| US-20080200448-A1 | reversible and selective purinergic receptor P2Y12 antagonists; anticoagulants; cardiovascular disorders; e.g. ethyl 2-acetoxy-6-{4-[(benzylsulfonyl)carbamoyl]piperidin-1-yl}-5-cyanonicotinate | P2RY12, P2RY13, P2RY11 | STS 2600/4885CA12 3505/4885CA1 4124/4885 |
| US-20080312208-A1 | Pyridine Analogues | P2RY12, P2RY11, P2RY1 | STS 2548/4885CA12 4725/4885CA1 4880/4885 |
| US-20100137277-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS | P2RY12, P2RY11, P2RY1 | STS 3011/4885CA12 4294/4885CA1 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.